Form 4: Vertex Pharmaceuticals Director Acquires Stock Options

Michel Lagarde, a director at Vertex Pharmaceuticals, acquired 3,142 stock options at an exercise price of $399.71 on May 1, 2024.

Summary

• On May 1, 2024, Michel Lagarde, a director of Vertex Pharmaceuticals, acquired 3,142 stock options.
• The exercise price for these options is $399.71.
• The options are fully vested and expire on April 30, 2034.
• Following the transaction, Lagarde directly owns 3,142 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation, and does not inherently indicate positive or negative sentiment.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, which is a common form of executive compensation in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, used to align management's interests with those of shareholders.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices of these options are generally benchmarked against industry standards to attract and retain talent.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially incentivizing them to work towards increasing the company's value.

Key Dates